NSG
GSK icon

Nalls Sherbakoff Group’s GSK GSK Stock Holding History

Nalls Sherbakoff Group’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.72K Sell
90
-232
-72% -$12.3K ﹤0.01% 308
2026
Q1 		$17.8K Hold
322
– – 0.01% 271
2025
Q4 		$15.8K Buy
322
+232
+258% +$10.8K 0.01% 296
2025
Q3 		$3.88K Hold
90
– – ﹤0.01% 369
2025
Q2 		$3.46K Hold
90
– – ﹤0.01% 371
2025
Q1 		$3.49K Buy
+90
New +$3.29K ﹤0.01% 355
2018
Q4 		$4K Buy
+90
New +$4.43K 0.01% 320

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Nalls Sherbakoff Group's GSK Position: Q2 2026 in Review

Nalls Sherbakoff Group reduced its GSK (GSK) stake by 72% in Q2 2026, selling an estimated $12.3K and leaving 90 shares worth $4.72K. The position accounts for ﹤0.01% of the portfolio, ranked #308.

Nalls Sherbakoff Group first reported a position in GSK in Q4 2018 and has held it in 7 quarters since. The position peaked at $17.8K in Q1 2026. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Nalls Sherbakoff Group held 90 shares of GSK worth $4.72K as of Q2 2026.
  • Nalls Sherbakoff Group sold 232 GSK shares in Q2 2026, an estimated $12.3K.
  • GSK made up ﹤0.01% of Nalls Sherbakoff Group's portfolio in Q2 2026, its #308 holding.
  • Nalls Sherbakoff Group first reported a position in GSK in Q4 2018 and has held it in 7 quarters since.
  • Nalls Sherbakoff Group's GSK position peaked at $17.8K in Q1 2026.
  • 1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Nalls Sherbakoff Group's 13F filing for Q2 2026, filed 17 Aug 2026.